GBG HOME

GBG Research at ASCO 2022

12.05.2022

GBG Research at ASCO 2022

We are happy to present our research at the ASCO Annual meeting June 2022.

GeparNuevo

Poster #354 6. Juni 2022, 15:00 MESZ
Poster Session: Breast Cancer—Local/Regional/Adjuvant
Presenter: Carsten Denkert
Biomarkers for response to immunotherapy in triple-negative breast cancer: Differences between survival and pCR biomarkers.
Denkert C, Schneeweiss A, Rey J, et al.

GeparNuevo

Poster #352 6. Juni 2022, 15:00 MESZ
Poster Session: Breast Cancer—Local/Regional/Adjuvant
Presenter: Thomas Karn
Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer.
Karn T, Denkert C, Rey J, et al.

Education Session

Integrating Immunotherapy in the Treatment Landscape of Patients With Triple-
Negative Breast Cancer
Presentation: Immunotherapy for Patients With Early-Stage Triple-Negative Breast Cancer: Is the Presence of Tumor Cells Required?
Speaker: Sibylle Loibl, MD, PhD, Time: June 7th 08:00-08:15 am CDT, Location: E450

PALLAS (External)

Poster discussion # 290 6. Juni 2022, 20:15 MESZ
Poster Discussion Session: Breast Cancer—Local/Regional/Adjuvant
Presenter: Georg Pfeiler
Impact of Body Mass Index on treatment and outcomes in early hormone receptor-positive breast cancer patients receiving endocrine therapy with or without palbociclib in the PALLAS trial.
Pfeiler G, et al.


News

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd